Financial Comparison: Biodel (ALBO) and RegeneRx Biopharmaceuticals (RGRX)
Biodel (NASDAQ: ALBO) and RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.
This is a summary of current recommendations and price targets for Biodel and RegeneRx Biopharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Biodel currently has a consensus target price of $61.67, suggesting a potential upside of 138.19%. RegeneRx Biopharmaceuticals has a consensus target price of $1.50, suggesting a potential upside of 646.27%. Given RegeneRx Biopharmaceuticals’ higher possible upside, analysts plainly believe RegeneRx Biopharmaceuticals is more favorable than Biodel.
Earnings & Valuation
This table compares Biodel and RegeneRx Biopharmaceuticals’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Biodel||$11.36 million||20.28||-$4.03 million||$2.17||11.93|
RegeneRx Biopharmaceuticals has higher revenue, but lower earnings than Biodel. RegeneRx Biopharmaceuticals is trading at a lower price-to-earnings ratio than Biodel, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Biodel has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, RegeneRx Biopharmaceuticals has a beta of -2.7, suggesting that its share price is 370% less volatile than the S&P 500.
This table compares Biodel and RegeneRx Biopharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
27.3% of Biodel shares are held by institutional investors. Comparatively, 0.1% of RegeneRx Biopharmaceuticals shares are held by institutional investors. 22.3% of Biodel shares are held by company insiders. Comparatively, 12.1% of RegeneRx Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Biodel beats RegeneRx Biopharmaceuticals on 9 of the 12 factors compared between the two stocks.
Biodel Inc. is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia. It also develops insulin formulations for Type 1 and Type 2 diabetes patients. Its product pipeline includes RHI-based Ultra-Rapid-Acting Insulin, Analog-based Ultra-Rapid-Acting Insulin, Concentrated Ultra-Rapid-Acting Insulin and Glucagon. The Company’s BIOD-531 is a Concentrated Ultra-Rapid-Acting Insulin and its insulin analog-based ultra-rapid-acting insulin product candidates include BIOD-123, BIOD-531, BIOD-238 and BIOD-250. It also conducts pre-clinical testing to develop liquid formulations of glucagon for hypoglycemic rescue and other indications.
About RegeneRx Biopharmaceuticals
RegeneRx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of a therapeutic peptide, Thymosin beta 4 (Tb4), for tissue and organ protection, repair and regeneration. The Company’s segment is the development and marketing of product candidates based on Tb4, an amino acid peptide. The Company has formulated Tb4 into three product candidates in clinical development: RGN-259, RGN-352 and RGN-137. Tb4 is a synthetic copy of a naturally occurring 43-amino acid peptide that is originally isolated from bovine thymus glands. RGN-259 is its preservative-free eye drop formulation of Tb4. RGN-352 is an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration. RGN-137 is a topical gel for dermal wounds and reduction of scar tissue.
Receive News & Ratings for Biodel Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodel Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.